JP2024517087A5 - - Google Patents
Info
- Publication number
- JP2024517087A5 JP2024517087A5 JP2023562610A JP2023562610A JP2024517087A5 JP 2024517087 A5 JP2024517087 A5 JP 2024517087A5 JP 2023562610 A JP2023562610 A JP 2023562610A JP 2023562610 A JP2023562610 A JP 2023562610A JP 2024517087 A5 JP2024517087 A5 JP 2024517087A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- weekly
- seq
- approximately
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163173919P | 2021-04-12 | 2021-04-12 | |
| US63/173,919 | 2021-04-12 | ||
| US202163219155P | 2021-07-07 | 2021-07-07 | |
| US63/219,155 | 2021-07-07 | ||
| US202263266880P | 2022-01-18 | 2022-01-18 | |
| US63/266,880 | 2022-01-18 | ||
| PCT/US2022/024354 WO2022221239A1 (en) | 2021-04-12 | 2022-04-12 | Compositions and methods for treating pediatric myasthenia gravis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024517087A JP2024517087A (ja) | 2024-04-19 |
| JP2024517087A5 true JP2024517087A5 (https=) | 2025-04-22 |
Family
ID=83640966
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023562610A Pending JP2024517087A (ja) | 2021-04-12 | 2022-04-12 | 小児重症筋無力症を治療するための組成物及び方法 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20240182598A1 (https=) |
| EP (1) | EP4323002A4 (https=) |
| JP (1) | JP2024517087A (https=) |
| KR (1) | KR20230169207A (https=) |
| AU (1) | AU2022256389A1 (https=) |
| BR (1) | BR112023021046A2 (https=) |
| CA (1) | CA3216642A1 (https=) |
| CL (1) | CL2023003033A1 (https=) |
| IL (1) | IL307445A (https=) |
| JO (1) | JOP20230247A1 (https=) |
| MX (1) | MX2023012032A (https=) |
| PH (1) | PH12023552841A1 (https=) |
| WO (1) | WO2022221239A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113518783A (zh) | 2018-07-20 | 2021-10-19 | 动量制药公司 | FcRn抗体组合物 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3081144A1 (en) * | 2017-12-08 | 2019-06-13 | Argenx Bvba | Use of fcrn antagonists for treatment of generalized myasthenia gravis |
| KR102904658B1 (ko) * | 2017-12-13 | 2025-12-29 | 모멘타 파머슈티컬스 인코포레이티드 | FcRn 항체 및 이의 사용 방법 |
| WO2019160979A1 (en) * | 2018-02-13 | 2019-08-22 | The Brigham And Women's Hospital, Inc. | Therapeutic fcrn-based bispecific monoclonal antibodies |
| WO2020023310A1 (en) * | 2018-07-20 | 2020-01-30 | Williams Eva | Compositions of fcrn antibodies and methods of use thereof |
-
2022
- 2022-04-12 US US18/286,455 patent/US20240182598A1/en active Pending
- 2022-04-12 BR BR112023021046A patent/BR112023021046A2/pt unknown
- 2022-04-12 JP JP2023562610A patent/JP2024517087A/ja active Pending
- 2022-04-12 AU AU2022256389A patent/AU2022256389A1/en active Pending
- 2022-04-12 IL IL307445A patent/IL307445A/en unknown
- 2022-04-12 WO PCT/US2022/024354 patent/WO2022221239A1/en not_active Ceased
- 2022-04-12 CA CA3216642A patent/CA3216642A1/en active Pending
- 2022-04-12 MX MX2023012032A patent/MX2023012032A/es unknown
- 2022-04-12 PH PH1/2023/552841A patent/PH12023552841A1/en unknown
- 2022-04-12 EP EP22788750.2A patent/EP4323002A4/en active Pending
- 2022-04-12 KR KR1020237038171A patent/KR20230169207A/ko active Pending
-
2023
- 2023-10-11 CL CL2023003033A patent/CL2023003033A1/es unknown
- 2023-10-12 JO JOJO/P/2023/0247A patent/JOP20230247A1/ar unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023548858A5 (https=) | ||
| Milo | Therapies for multiple sclerosis targeting B cells | |
| CN103930444B (zh) | 用前蛋白转化酶枯草溶菌素-9(PCSK9)抑制剂降低脂蛋白(a)水平的方法 | |
| CN107922507B (zh) | 抗pcsk9抑制性抗体用来治疗接受脂蛋白单采的高脂血症患者 | |
| JP2017160208A5 (https=) | ||
| CN113195540A (zh) | 提供皮下施用抗cd38抗体的方法 | |
| CN111787981B (zh) | 增加肌肉量和减少脂肪量的方法 | |
| JP2024102205A5 (https=) | ||
| JP2022515770A5 (https=) | ||
| JP2015533806A (ja) | 関節リウマチの治療 | |
| JP2016069373A (ja) | 抗ｐｃｓｋ９抗体を用いた処置 | |
| CN118105485B (zh) | 一种稳定的抗人IL-4Rα单克隆抗体制剂 | |
| JP2025514142A5 (https=) | ||
| WO2021100794A1 (ja) | 抗体含有製剤 | |
| CN114344460B (zh) | 含有抗pcsk9抗体的稳定制剂及其制备方法和用途 | |
| EP4387999A1 (en) | Ofatumumab for treating pediatric ms | |
| JP2024517087A5 (https=) | ||
| WO2020088492A1 (zh) | 含有抗pcsk9抗体的稳定制剂 | |
| US12139546B2 (en) | Methods of treating urea cycle disorders by interfering with glucagon receptor signaling | |
| JP2023531722A5 (https=) | ||
| JP2022527542A5 (https=) | ||
| WO2020063668A1 (zh) | 包含抗ox40抗体的制剂、其制备方法及其用途 | |
| WO2023134771A1 (zh) | 抗ctla-4抗体药物组合物及其用途 | |
| JP2022502380A5 (https=) | ||
| TW202114734A (zh) | Il-17拮抗劑治療自身免疫疾病的方法 |